Active MMP-2 effectively identifies the presence of colorectal cancer
Corresponding Author
Mary Jo Murnane
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA
Department of Biochemistry, Boston University School of Medicine, Boston, MA
Fax: 617-414-7073.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany St--4th floor, Boston, 02118 MASearch for more papers by this authorJinguo Cai
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA
Search for more papers by this authorSania Shuja
Department of Pathology, University of Florida College of Medicine, Jacksonville, FL
Search for more papers by this authorDavid McAneny
Department of Surgery, Boston University School of Medicine, Boston, MA
Search for more papers by this authorVeronica Klepeis
Department of Pathology, Massachusetts General Hospital, Boston, MA
Search for more papers by this authorJohn B. Willett
Graduate School of Education, Harvard University, Cambridge, MA
Search for more papers by this authorCorresponding Author
Mary Jo Murnane
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA
Department of Biochemistry, Boston University School of Medicine, Boston, MA
Fax: 617-414-7073.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany St--4th floor, Boston, 02118 MASearch for more papers by this authorJinguo Cai
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA
Search for more papers by this authorSania Shuja
Department of Pathology, University of Florida College of Medicine, Jacksonville, FL
Search for more papers by this authorDavid McAneny
Department of Surgery, Boston University School of Medicine, Boston, MA
Search for more papers by this authorVeronica Klepeis
Department of Pathology, Massachusetts General Hospital, Boston, MA
Search for more papers by this authorJohn B. Willett
Graduate School of Education, Harvard University, Cambridge, MA
Search for more papers by this authorAbstract
Fully active MMP-2 is expressed at such low levels in human tissues that studies often fail to confirm its value as a cancer marker despite strong associations with malignancy. Our study utilized careful extraction, accurate activity measurements, standardization to purified controls and a new statistical metric to determine whether active MMP-2 is an effective indicator of colorectal cancer compared to pro-MMP-2 or pro-MMP-9. MMP-2 and MMP-9 activities were analyzed in matched normal and cancer samples from 269 patients by gelatin zymography, computer-assisted image analysis, serial dilutions of strong samples and standardization to controls. An index of effect size was designed for comparative evaluation of active MMP-2, pro-MMP-2 and pro-MMP-9 activities. For each gelatinase, mean activity and protein levels/mg soluble protein in normal mucosa and colorectal cancer were calculated for the first time with respect to commercial standards. Active MMP-2 activity, detected in 99% of colorectal cancers, was higher in 95% of cancers (on average 10-fold) than in normal mucosa. Levels of pro-MMP-2 and pro-MMP-9, but not active MMP-9, activities were also significantly higher in cancers versus normal. However, active MMP-2 activity provided the most effective test for the presence of cancer (p < 0.0.0001) with an effect size statistically significantly larger than for either pro-MMP-2 or pro-MMP-9. Receiver operating characteristic (ROC) curves demonstrated that a cut-off for active MMP-2 of >44 SDU activity/mg soluble protein (>180 pg/mg), which is three times mean normal levels, would permit detection of colorectal cancer with an estimated sensitivity of 84% and estimated specificity of 93%. © 2009 UICC
References
- 1 Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415–33.
- 2 Vansaun MN,Matrisian LM. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 2006; 78: 69–79; Review.
- 3 Page-Mccaw A,Ewald AJ,Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007; 8: 221–33.
- 4 Mook ORF,Frederiks WM,Van Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69–89.
- 5 Björklund M,Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37–96.
- 6 Garbett EA,Reed MWR,Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer 1999; 81: 287–93.
- 7 Gimeno-Garcia AZ,Santana-Rodriguez A,Jimenez A,Parro-Blanco A,Nicholas-Perez D,Paz-Cabrera C,Diaz-Gonzalez F,Medina C,Diaz-Flores L,Quintero E. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur J Cancer 2006; 42: 3146–252.
- 8 Koshiba T,Hosotani R,Wada M,Fujimoto K,Lee J-U,Doi R,Arii S,Imamura M. Detection of Matrix Metalloproteinase Activity in Human Pancreatic Cancer. Surg Today Jpn J Surg 1997; 27: 302–4.
- 9 Nakamura H,Ueno H,Yamashita K,Shimada T,Yamamoto E,Noguchi M,Fujimoto N,Sato H,Seiki M,Okada Y. Enhanced Production and Activation of Progelatinase A Mediated by Membrane-Type 1 Matrix Metalloproteinase in Human Papillary Thyroid Carcinomas. Cancer Res 1999; 59: 467–73.
- 10
Nomura H,Fujimoto N,Seiki M,Mai M,Okada Y.
Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas.
Int J Cancer (Pred Oncol)
1996;
69:
9–16.
10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 11 Patel BP,Shah SV,Shukla SN,Shah PM,Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007; 29: 564–72.
- 12 Sheu B-C,Lien H-C,Ho H-N,Lin H-H,Chow S-N,Huang S-C,Hsu S-M. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63: 6537–42.
- 13 Torng P-L,Mao T-L,Chan W-Y,Huang S-C,Lin C-T. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004; 92: 559–67.
- 14 Kleiner DE,Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42–S51.
- 15 Hofmann U,Eggert AAO,Blass K,Brocker E-B,Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003; 63: 8221–5.
- 16 Coussens LM,Fingleton B,Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–92.
- 17 American Joint Committee on Cancer, Manual for staging cancer, 3rd ed. Philadelphia: J.B. Lippincott, 1988.
- 18 Nichols EA,Ruddle FH. A review of enzyme polymorphism, linkage and electrophoretic conditions for mouse and somatic cell hybrids in starch gel. J Histochem 1973; 21: 1066–81.
- 19 Lowry OH,Rosebrough NJ,Farr AL,Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75.
- 20 Rao JS,Steck PA,Mohanam S,Stetler-Stevenson WG,Liotta L,Sawaya R. Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res 1993; 53: 2208–11.
- 21 Murnane MJ,Shuja S,Del Re E,Cai J,Iacobuzio-Donahue C,Klepeis V. Characterizing human colorectal carcinomas by proteolytic profile. In vivo 1997; 11: 209–16.
- 22 Itoh Y,Binner S,Nagase H. Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J 1995; 308: 645–51.
- 23 Birkedal-Hansen H,Taylor RE. Detergent-activation of latent collagenase and resolution of its component molecules. Biochem Biophys Res Commun 1982; 107: 1173–8.
- 24 Murnane MJ,Cai J,Shuja S,Cote L,Delre E,Iacobuzio-Donahue C,Kim K,Sheahan K. Changing patterns of proteolytic expression with colorectal tumor progression. In: M Suzuki, T Hiwasa, eds. Proteases Involved in Cancer. Bologna: Monduzzi Editore, 1994. 1–11.
- 25 Xia T,Akers K,Eisen AZ,Seltzer JL. Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. Biochim Biophys Acta 1996; 1293: 259–66.
- 26 Kolkenbrock H,Hecker-Kia A,Orgel D,Kinawi A,Ulbrich N. Progelatinase B forms from human neutrophils. Complex formation of monomer/lipocalin with TIMP-1. Biol Chem 1996; 377: 529–33.
- 27 Mosteller F,Tukey JW. Data analysis and regression: a second course in statistics. Reading, MA: Addison-Wesley, 1977.
- 28
Cohen J.
Statistical power analysis for the behavioral sciences,
2nd ed.
Hillsdale NJ:
Lawrence Erlbaum Associates,
1988.
10.1046/j.1526-4610.2001.111006343.x Google Scholar
- 29 Hedges LV,Olkin I. Statistical methods for meta-analysis. NY: Academic Press, 1985.
- 30 Rosner B. Fundamentals of biostatistics. Pacific Grove,CA: Duxbury, 2000. 63–65.
- 31 Davies B,Miles DW,Happerfield LC,Naylor MS,Bobrow LC,Rubens RD,Balkwill FR. Activity of type IV collagenases in benign and malignant breast tissue. Br J Cancer 1993; 76: 1126–34.
- 32 Waas ET,Lomme RM,Degroot J,Wobbes T,Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876–83.
- 33 Waas ET,Wobbes T,Lomme RM,Degroot J,Ruers T,Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90: 1556–64.
- 34 Yamagata S,Yoshii Y,Suh JG,Tanaka R,Shimizu S. Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer lett 1991; 59: 51–5.
- 35 Parsons SL,Watson SA,Collins HM,Griffin NR,Clarke PA,Steele RJ. Gelatinase (MMP-2 and 9) expression in gastrointestinal malignancy. Br J Cancer 1998; 78: 1495–1502.
- 36 Emmert-Buck MR,Roth MJ,Zhuang Z,Campo E,Rozhin J,Sloane BF,Liotta LA,Stetler-Stevenson WG. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994; 145: 1285–90.
- 37 Liabakk N-B,Talbot I,Smith RA,Wilkinson K,Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type VI collagenases in colorectal cancer. Cancer Res 1996; 56: 190–6.
- 38 Zeng ZS,Cohen AM,Guillem JG. Loss of basement. membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999; 20: 749–55.
- 39 Papadopoulou S,Scorilas A,Arnogianaki N,Papapanayiotou B,Tzimogiani A,Agnantis N,Talieri M. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 2001; 22: 383–389.
- 40 Yan SJ,Bloome EAG. In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. Vet Pathol 2003; 40: 227–36.
- 41 Hilska M,Roberts PJ,Collan YU,Laine VJ,Kössi J,Hirsimäki P,Rahkonen O,Laato M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 21: 714–23.
- 42
Li M,Li J-Y,Zhao A-L,He A-S,Zhou L-X,Li Y-A,Gu J.
Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1.
Dis Colon Rectum
2007;
50:
1887–98.
10.1007/s10350-007-9053-y Google Scholar
- 43 Tomita T,Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996; 39: 1255–64.
- 44 Mook ORF,Van Overbeek C,Ackema EG,Van Maldegem F,Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat. J Histochem Cytochem 2003; 51: 821–9.
- 45 Kleiner DE,Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325–9.
- 46 Maquoi E,Frankenne F,Noel A,Krell H-W,Grams F,Foidart J-M. Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp Cell Res 2000; 261: 348–59.
- 47 Hrabec E,Strek M,Nowak D,Greger J,Suwalski M,Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol 2002; 128: 197–204.